AMT-562 / Multitude Therap - LARVOL DELTA

AMT-562 in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Multitude Therapeutics (Australia) Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

Puzhong discovered that a new ADC targeting HER3 has been approved for clinical use [Google translation] (163.com) - "The official website of the Center for Drug Evaluation (CDE) of the China State Food and Drug Administration announced that AMT-562, a Class 1 new drug for injection applied by Multiitude Therapeutics, has been approved for clinical use and is planned to be developed to treat advanced solid tumors."

New trial • Oncology • Solid Tumor

AMT-562 in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Multitude Therapeutics (Australia) Pty Ltd

Metastases • New P1 trial • Oncology • Solid Tumor